REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
 
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > O-glycoside > > Nitrogen Containing Hetero Ring > Purines (including Hydrogenated) (e.g., Adenine, Guanine, Etc.) > Adenosine Or Derivative Adenosine Or DerivativeAdenosine Or Derivative patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.12/28/06 - 20060293274 - N²-quinoline or isoquinoline substituted purine derivatives wherein W represents a hydrogen, an optionally substituted C1-6 alkyl, an optionally substituted C3-6 cycloalkyl, or an optionally substituted C1-6 haloalkyl, Y represents a hydrogen, or a saccharide, Q represents a quinoline or isoquinoline. Also disclosed are a pharmaceutical compositions comprising the same, methods for treating cancer using the same, ... 09/28/06 - 20060217344 - Compounds for the treatment of tobacco dependence and withdrawal The invention provides methods for treating or suppressing tobacco or nicotine usage or dependence involving administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, creatine-containing compound, adenosine-containing, or adenosine-elevating compound to a mammal. ... 09/28/06 - 20060217343 - 2-polycyclic propynyl adenosine analogs having a2a agonist activity wherein X, R1, R2, R7 and Z are as described herein. ... 08/17/06 - 20060183708 - Topical delivery of trace metals for enzyme modulation The present invention relates to a method for topical delivery of trace metals for the modulation of certain metalloenzymes. The method of topical delivery of the present invention comprises; (i) mixing of a trace metal salt of a phosphorylated nitrogen heterocyclic base complexed with a chelating agent [FIG. 1], and ... 07/27/06 - 20060166925 - Substitution derivatives of n6-benzyladenosine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compou The invention concerns novel substitution derivatives of N6-benzyladenosine having anticancer, mitotic, immunosuppressive and antisenescent properties for plant, animal and human cells. This invention also relates to the methods of preparation of these N6-benzyladenosine derivatives and their use as drugs, cosmetic preparations and growth regulators comprising these derivatives as active compound ... 06/22/06 - 20060135467 - Partial and full agonists of a1 adenosine receptors Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular the supraventricular tachycardias, emesis, angina, myocardial infarction and hyperlipidemia. ... 06/22/06 - 20060135466 - Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs Provided is a method for the synthesis of an aralkyloxyadenosine or an alkoxyadenosine. The method includes protecting the hydroxyl sugar groups with a protecting group to produce a protected halogenated adenosine. The protected halogenated adenosine is alkoxylated, and the hydroxyl sugar groups of the protected halogenated adenosine are deprotected to ... 06/22/06 - 20060135465 - Synthesis and use of 2'-substituted-n6-modified nucleosides An improved method of preparing a sugar modified nucleoside analog includes a protocol in which a hydroxy group of a sugar is selectively deprotected and oxidized prior to nucleophilic modification of the corresponding carbonyl group. The modified sugar is then coupled to a heterocyclic base that is modified with a ... 06/15/06 - 20060128652 - Purine derivatives and methods of use thereof The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for treating or preventing an ischemic condition, reperfusion injury, a cellular proliferative disorder, a cardiovascular disease, a neurological disorder, a skin disorder, a radiation-induced injury, a wound, or an inflammatory disease comprising administering ... 06/08/06 - 20060122145 - 2-aminocarbonyl-9h-purine derivatives and pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds. ... 06/08/06 - 20060122144 - Compounds resistant to metabolic deactivation and methods of use Therapeutic compounds having increased resistance to deamination and inactivation by metabolic enzymes are provided. The compounds include nucleotide analogs and nucleotide analogs, derivatized with aminal and/or thioaminal groups to prevent deamination of free amine. The compounds can be used in a variety of treatments, including treatment of neoplastic disorders, infections ... 05/11/06 - 20060100169 - Method to reduce an inflammatory response from arthritis The present invention provides a therapeutic method for treating an inflammatory response caused by autoimmune stimulation, comprising the administration to a patient in need thereof of an antiinflammatory amount amount of an A2A adenosine receptor agonist. The autoimmune stimulation can be caused by arthritis, particularly rheumatoid arthritis. Optionally, the method ... 05/11/06 - 20060100168 - Method of treating cancer using adenosine and its analogs The present invention provides methods of treating individuals having malignancies associated with estrogen receptor activity comprising administering to an individual affected with said malignancy, an effective amount of adenosine analog in a pharmaceutical carrier to downregulate or diminish estrogen receptors in the cells. The invention further provides methods of identifying ... 04/20/06 - 20060084626 - Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist Adenosine receptor agonists, particularly an agonist which binds to the A3 adenosine receptor, are used for induction of production or secretion of G-CSF within the body, prevention or treatment of toxic side effects of a drug or prevention or treatment of leukopenia, particularly drug-induced leukopenias; and inhibition of abnormal cell ... 04/20/06 - 20060084625 - Use of a2a adenosine receptor agonists Myocardial imaging methods that are accomplished by administering doses of a pharmaceutical composition including regadenoson—an adenosine A2A receptor agonist—to a human undergoing myocardial imaging in an amount sufficient to achieve at least a minimal increase in average coronary peak flow velocity. ... 04/20/06 - 20060084624 - Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis b wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The ... 02/23/06 - 20060040889 - 2-polycyclic propynyl adenosine analogs having a2a agonist activity wherein X, R1, R2, R7 and Z are as described herein. ... 02/23/06 - 20060040888 - 2-propynyl adenosine analogs with modifed 5'-ribose groups having a2a agonist activity wherein X, R1, R2, R7 and Z are as described herein. ... 01/12/06 - 20060009417 - A1 adenosine receptor agonists wherein R is optionally substituted phenyl, that are useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction. ... 12/22/05 - 20050282769 - Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage Methods for preventing and treating damage to the optic nerve and/or retina with adenosine kinase inhibitors are disclosed. ... 12/15/05 - 20050277615 - Pharmaceutical compositions having anti-inflammatory activity R3 represents a lower alkyl, lower cycloalkyl, aryl, (ar)alkyl or anilide, said cycloalkyl, aryl and (ar)alkyl may be substituted with one or more of the groups selected from halogen, hydroxyl, hydroxyalkyl; and a pharmaceutically acceptable additive. The composition may be used to threat diseases such as multiple sclerosis, rheumatoid arthritis ... 12/08/05 - 20050272687 - Stable s-adenosyl-l-methionine Stable conjugates of S-adenosyl-1-methionine, methods for their synthesis and methods for their uses are described. The conjugates according to the invention are very stable and are valuable for use as active constituents in pharmaceutical compositions. ... 11/24/05 - 20050261236 - Agonists of a2a adenosine receptors for treatment of diabetic nephropathy The present invention provides a therapeutic method for treating diabetic kidney disease, e.g., diabetic nephropathy that includes the administration of an effective amount of an A2A adenosine receptor agonist. Optionally, the method includes administration of a type IV PDE inhibitor. ... 11/10/05 - 20050250729 - Novel adenosine a3 receptor agonists wherein Ar, R and R1 have the meanings given in the specification. This series of sulfonamido derivatives with a conserved uronamide group at the 5′ position provide superior A3 receptor affinity as well as selectivity. These new adenosine agonists are sulfonamido derivatives N-substituted with aliphatic groups (cyclic or linear) or ... 09/29/05 - 20050215512 - 4' -c-substituted-2-haloadenosine derivative (wherein X represents a halogen atom, R1 represents an ethynyl group or a cyano group, and R2 represents hydrogen, a phosphate residue, or a phosphate derivative residue). The present invention also provides a pharmaceutical composition containing the derivative and a pharmaceutically acceptable carrier therefor. ... 09/01/05 - 20050192244 - Histamine release inhibitor <10> N-hydroxy-N-methyl-adenosine derived from Phellinus linteus ... 09/01/05 - 20050192243 - Neuromuscular blocking agents and antagonists thereof The invention provides methods and kits for reversing the effects of ultra-short and intermediate duration halofumarate neuromuscular blocking agents that involve the use of cysteine and cysteine-like antagonists. ... 08/18/05 - 20050182019 - Phosphonate compounds The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like. ... 08/18/05 - 20050182018 - Method to reduce inflammatory response in transplanted tissue The present invention provides a therapeutic method for treating biological diseases that includes the administration of an effective amount of a suitable antibiotic agent, antifungal agent or antiviral agent in conjunction with an A2A adenosine receptor agonist. If no anti-pathogenic agent is known the A2A agonist can be used alone ... 08/11/05 - 20050176675 - Stable and active complexes of adenosine and adenosine phosphates with aminoalcohols for the treatment of pulmonary artery hypertension, cardiac failure and other diseases The invention is directed to compositions and methods which permit the oral use of adenosine and adenosine phosphates for cardiovascular applications such as pulmonary artery hypertension, cardiac failure and other diseases. Certain compositions in accordance with the invention have enhanced AMP gastrointestinal bioavailability and thus efficacy. The invention prolongs the ... 08/11/05 - 20050176674 - Composition and method for use in cartilage affecting conditions A method for decreasing cartilage abnormalities in an animal in need of such decrease which comprises systemically administering to said animal a cartilage abnormality decreasing effective amount of a combination of at least one sulfur containing amino acid and manganese. ... 08/04/05 - 20050171050 - Organ arrest, protection and preservation The present invention relates to a method for arresting, protecting and/or preserving an organ which includes administering effective amounts of (i) potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) local anaesthetic to a subject in need thereof. The present invention also relates to a method for ... 06/23/05 - 20050137162 - new comt inhibitors for the treatment of depression and impaired cognition and to esters thereof which are hydrolyzable under physiological conditions and to the pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of COMT and, thus, are useful for the treatment of diseases for which COMT inhibition is beneficial. The invention further relates to the treatment, control, or ... 06/16/05 - 20050130930 - Adenosine derivatives and use thereof 2-(6-Cyano-1-hexyn-1-yl)adenosine, 2-(6-cyano-1-hexyn-1-yl)adenosine 5′-monophosphate, or salts thereof; and drugs containing the same as an active ingredient. The compounds have excellent effects of lowering ocular tension, promoting blood flow in retina, and protecting optic nerve failure and are highly soluble in water. Owing to these characteristics, the compounds are useful as drugs ... ### FreshPatents.com Support - Terms & Conditions |